5 recruiting, 4 completed, 3 active not recruiting, 3 unknown. 17 Phase 2, 7 Phase 1.
Follow Non-muscle Invasive Bladder Cancer: new trials by email Literature Review of Non-muscle Invasive Bladder Cancer trials Research Report on Non-muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer Durvalumab, Monalizumab - Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | John Sfakianos | 60 | 2025-02-24 | 2026-10-05 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 35 | 2024-12-20 | 2026-11-05 |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Disitamab vedotin, Bacillus Calmette Guerin Vaccine - Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | Active not recruiting | Fudan University | 20 | 2023-12-18 | 2026-07-20 |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer TARA-002 - Non-muscle Invasive Bladder Cancer | Phase 2 | Recruiting | Protara Therapeutics | 131 | 2023-09-15 | 2026-08-24 |
| RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression RC48, Tislelizumab - Non-Muscle Invasive Bladder Cancer, HER2 | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-08-05 | 2023-08-31 |
| RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer RC48-ADC - Non-muscle Invasive Bladder Cancer | Phase 2 | Unknown | West China Hospital | 77 | 2023-08-01 | 2023-08-18 |
| A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer Bicalutamide, Control Arm - Non-Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | CHU de Quebec-Universite Laval | 160 | 2022-06-23 | 2026-10-26 |
| Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11 - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 115 | 2021-11-08 | 2026-08-14 |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) - Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 1 / Phase 2 | Recruiting | enGene, Inc. | 350 | 2021-04-22 | 2026-08-07 |
| Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention eRapa, Placebos - Non-muscle Invasive Bladder Cancer | Phase 2 | Active not recruiting | Robert Svatek | 166 | 2021-01-25 | 2026-06-03 |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Pemigatinib - Bladder Cancer, NMIBC | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2020-10-02 | 2025-10-03 |
| A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer alpha1H, 7.4 mg/mL, placebo, alpha1H, 37 mg/mL - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Hamlet Pharma AB | 52 | 2018-05-21 | 2020-08-19 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer TSD-001 - Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Lipac Oncology LLC | 15 | 2018-05-17 | 2025-06-27 |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation) - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | ImmunityBio, Inc. | 369 | 2014-07-21 | 2026-03-31 |
| Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy APL-1202 treatment - Non-muscle Invasive Bladder Cancer | Phase 2 | Completed | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 41 | 2014-05-13 | 2020-08-13 |
| A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer ALT-801, Gemcitabine - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Terminated | Altor BioScience | 12 | 2012-03-30 | 2024-07-19 |
Non-Muscle Invasive Bladder Neoplasms (17) · Urinary Bladder Neoplasms (8) · Carcinoma in Situ (3) · Carcinoma, Transitional Cell (3) · Neoplasms (3) · Recurrence (1) · Urinary Bladder Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Carcinoma (17) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Urogenital Diseases (17) · Urinary Bladder Diseases (16) · Urogenital Neoplasms (16) · Urologic Diseases (16) · Urologic Neoplasms (16) · Neoplasms (14) · Urinary Bladder Neoplasms (9) · Disease Attributes (1)
Gemcitabine (2) · disitamab vedotin (2) · ALT-801 (1) · ALT-803 (1) · BCG Vaccine (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Docetaxel (1) · Epirubicin (1) · Mitomycin (1) · Nonsteroidal Anti-Androgens (1) · Surface-Active Agents (1) · bicalutamide (1) · durvalumab (1) · monalizumab (1)
Altor BioScience (1) · CHU de Quebec-Universite Laval (1) · Fudan University (1) · Hamlet Pharma AB (1) · Hospital Centre Biel/Bienne (1) · ImmunityBio, Inc. (1) · Jiangsu Yahong Meditech Co., Ltd aka Asieris (1) · John Sfakianos (1) · Lipac Oncology LLC (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Protara Therapeutics (1) · RenJi Hospital (1) · Robert Svatek (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (10) · Canada (4) · China (3) · France (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Czechia (1) · Germany (1) · India (1) · Italy (1) · Japan (1)
Bernard Bochner, MD (1) · Bobby Reddy, MD (1) · Christine Tosone, Ms, RAC (1) · Dingwei Ye (1) · Dingwei Ye, MD,PhD (1) · Girish Kulkarni, BSc, MD, PhD, FRCSC (1) · Hao Zeng (1) · Jean-Baptiste Lattouf, MD,FRCSC (1) · John Sfakianos, MD (1) · Marek Babjuk, MD, Prof. (1) · Melissa Huynh, MD,MPH,FRCSC (1) · Michael Oefelein, MD (1) · Noah M Hahn, MD (1)
PMID 34103518, PMID 38553868, PMID 38953850, PMID 42337683
2016 (1), R01CA252057 (1)